Physician profile
Ashley E Rollins
NPI 1053700542
$1,321.21
in general payments reported to CMS, 2019-2025
25 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $34.81 · 2021: $165 · 2022: $201 · 2023: $231 · 2024: $183 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $196.10 | 2019-2023 | |
| Abbott Laboratories | $163.67 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $137.00 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $130.76 | 2020-2025 | |
| Amgen INC. | $98.75 | 2019-2025 | Otezla, Repatha |
| Antares Pharma, INC. | $63.68 | 2022 | |
| Lilly USA, LLC | $62.34 | 2019-2024 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $53.96 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $49.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.66 | 2019-2022 | |
| Welch Allyn | $44.55 | 2021 | |
| Astellas Pharma US INC | $33.53 | 2021-2025 | Veozah |
| Glaxosmithkline, LLC. | $32.74 | 2022-2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $32.42 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $28.07 | 2023 | Rexulti, Abilify Maintena |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.95 | 2019-2022 | |
| Vivus LLC | $19.76 | 2024 | Pancreaze |
| Novartis Pharmaceuticals Corporation | $18.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.16 | 2019 | |
| Minerva Surgical, INC | $13.93 | 2019 | |
| Merck Sharp & Dohme LLC | $12.69 | 2019 | |
| Insulet Corporation | $11.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.56 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.25 | 2020 | |
| Seqirus USA INC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Rollins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.